61
views
0
recommends
+1 Recommend
1 collections
    1
    shares

      Call for 2023 Manuscripts Now Open
      Submission Portal: https://lnkd.in/dpRQZYw

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Health Datasets as Assets: Blockchain-Based Valuation and Transaction Methods

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is increasing recognition about health-oriented datasets that could be regarded as intangible assets: distinct assets with future economic benefits but without physical properties. While health-oriented datasets – particularly health records – are ascribed monetary value on the black market, there are few established methods for assessing the value for legitimate research and business purposes. The emergence of blockchain has created new commercial opportunities for transferring assets without intermediaries. Therefore, blockchain is proposed as a medium by which research datasets could be transacted to provide future value. For authorized individuals to verify their transactions, blockchain methodologies offer security, auditability, and transparency. The authors share data valuation methodologies consistent with accounting principles and include discussions of black market valuation of health data. Furthermore, this article describes blockchain-based methods of managing real-time payment/micropayment strategies.

          Related collections

          Most cited references81

          • Record: found
          • Abstract: found
          • Article: not found

          FDA Approval: Blinatumomab.

          On December 3, 2014, the FDA granted accelerated approval of blinatumomab (Blincyto; Amgen, Inc.) for treatment of Philadelphia chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R ALL). Blinatumomab is a recombinant murine protein that acts as a bispecific CD19-directed CD3 T-cell engager. The basis for the approval was a single-arm trial with 185 evaluable adults with R/R ALL. The complete remission (CR) rate was 32% [95% confidence interval (CI), 26%-40%], and the median duration of response was 6.7 months. A minimal residual disease response was achieved by 31% (95% CI, 25%-39%) of all patients. Cytokine release syndrome and neurologic events were serious toxicities that occurred. Other common (>20%) adverse reactions were pyrexia, headache, edema, febrile neutropenia, nausea, tremor, and rash. Neutropenia, thrombocytopenia, and elevated transaminases were the most common (>10%) laboratory abnormalities related to blinatumomab. A randomized trial is required in order to confirm clinical benefit.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare

            The increased availability of data and recent advancements in artificial intelligence present the unprecedented opportunities in healthcare and major challenges for the patients, developers, providers and regulators. The novel deep learning and transfer learning techniques are turning any data about the person into medical data transforming simple facial pictures and videos into powerful sources of data for predictive analytics. Presently, the patients do not have control over the access privileges to their medical records and remain unaware of the true value of the data they have. In this paper, we provide an overview of the next-generation artificial intelligence and blockchain technologies and present innovative solutions that may be used to accelerate the biomedical research and enable patients with new tools to control and profit from their personal data as well with the incentives to undergo constant health monitoring. We introduce new concepts to appraise and evaluate personal records, including the combination-, time- and relationship-value of the data. We also present a roadmap for a blockchain-enabled decentralized personal health data ecosystem to enable novel approaches for drug discovery, biomarker development, and preventative healthcare. A secure and transparent distributed personal data marketplace utilizing blockchain and deep learning technologies may be able to resolve the challenges faced by the regulators and return the control over personal data including medical records back to the individuals.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Understanding platform business models: A mixed methods study of marketplaces

                Bookmark

                Author and article information

                Journal
                Blockchain Healthc Today
                Blockchain Healthc Today
                BHTY
                Blockchain in Healthcare Today
                Partners in Digital Health
                2573-8240
                22 March 2022
                2022
                : 5
                : 10.30953/bhty.v5.185
                Affiliations
                BurstIQ, Inc., Denver, Colorado, USA
                Author notes
                Correspondence: Wendy M. Charles. Email: wendy.charles@ 123456cuanschutz.edu
                Author information
                https://orcid.org/0000-0003-1627-6899
                https://orcid.org/0000-0002-6435-0769
                Article
                185
                10.30953/bhty.v5.185
                9907414
                44b70613-d301-4153-9647-8910c4202701
                © 2022 The Authors.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, adapt, enhance this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

                History
                : 10 November 2021
                : 19 December 2021
                : 21 December 2021
                Categories
                Narrative/Systematic Reviews/Meta-Analysis

                blockchain,data sales,data valuation,health records assets,intangible

                Comments

                Comment on this article